Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1661923

This article is part of the Research TopicImmuno-metabolic Approaches for the Treatment of Hepatobiliary and Pancreatic TumorsView all 8 articles

Prognostic analysis of different postoperative adjuvant therapies for patients with hepatocellular carcinoma after radical resection with high-risk recurrence factors : A multicenter real-world retrospective study

Provisionally accepted
  • 1Affiliated Hospital of Chengde Medical University, Chengde, China
  • 2The Second Hospital of Hebei Medical University, Shijiazhuang, China
  • 3Tangshan People's Hospital, Tangshan, China

The final, formatted version of the article will be published soon.

Background: Hepatocellular carcinoma is one of the most common malignant tumors worldwide, with high postoperative recurrence rates significantly limiting long-term survival, particularly in patients with high-risk features such as large tumor diameter, multiple tumor, microvascular invasion, or portal vein tumor thrombus. There is still considerable controversy about the efficacy of adjuvant therapy after liver resection in improving the prognosis of HCC patients with high risk of recurrence and its therapeutic efficacy in different high-risk subgroups. Materials and methods: This multicenter retrospective study included 300 patients with high-risk HCC who underwent liver resection in four medical institutions in China from January 2015 to April 2024, including 101 patients in the LR group and 199 patients in the LR+ postoperative adjuvant therapy group. Results: During follow-up, 178 patients (59.3%) died. OS was significantly better in the LR plus adjuvant therapy group than in the LR alone group (entire cohort: HR=0.55, 95% CI: 0.39–0.76, P<0.001; matched cohort: HR=0.47, 95% CI: 0.32–0.71, P<0.001). The median OS in the matched cohort was 32.1 months (95% CI: 25.4-38.8) for the adjuvant group versus 18.5 months (95% CI: 14.2-22.8) for the LR group. In the matched cohort, 1-, 3-, and 5-year OS rates were 82.2%, 46.0%, and 20.2% for the adjuvant group versus 63.4%, 33.1%, and 17.2% for the LR group. DFS was also significantly prolonged in the adjuvant group (HR=0.43, 95% CI: 0.29–0.65, P< 0.001), with a median DFS of 15.3 months (95% CI: 11.9-18.7) compared to 8.1 months (95% CI: 6.5-9.7) in the LR group, and 1-year DFS of 53.4% vs 30.9%. Multivariate analyses identified AFP, ALB, tumor diameter, PVTT, TACE, and adjuvant therapy as independent predictors of OS, while AFP, multiple tumors, MVI, PVTT, TACE, and adjuvant therapy were associated with DFS. Subgroup analysis showed that TACE offered significant benefit (OS: HR=0.54; DFS: HR=0.55), and TKI therapy also demonstrated improved outcomes (OS: HR=0.58; DFS: HR=0.58). Conclusion: Postoperative adjuvant therapy provides significant survival benefits for HCC patients with high risk of recurrence, with TACE therapy demonstrating the greatest efficacy. These findings underscore the importance of individualized postoperative management in this population.

Keywords: Hepatocellular Carcinoma, High-risk recurrence, Postoperative adjuvant therapy, propensity matching analysis, Real-world study

Received: 08 Jul 2025; Accepted: 09 Oct 2025.

Copyright: © 2025 Zhao, Xiao, Su, Zhao, Li and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Jinlong Liu, liujl800813@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.